Skip to main content
News & Events

Panel discussion: European annual biotech conference Biotech Atelier 2021

By September 29, 2021October 14th, 2021No Comments

BiomeDx was invited to present its own research and discuss microbiome and nutrigenetics.

September 29th, 2021: At the European annual biotech conference Biotech Atelier 2021 ( BiomeDx presented its current research giving an introduction on its myBioma product and the current state of BiomeOne. Interesting facts on the microbial diversity trend of Europeans during the COVID-19 pandemic and the future of fecal microbiota transplants were discussed.

The conference was a great opportunity to meet and discuss with international microbiome researchers on topics of cancer treatment, aging and nutrigenetics.

Dr. Nikolaus Gasche from BiomeDx

About BiomeOne®

BiomeOne describe the current efforts of BiomeDx towards the world’s first stool-based response prediction test for immunotherapy (ICI). Currently, the biomarker is tested in three tumor types: non-small-cell lung cancer, renal cell carcinoma and malignant melanoma. Early research efforts support the idea of a tumor agnostic biomarker, that can be used for any tumor type. Read more on BiomeOne®.

About BiomeDx®

Biome Diagnostics GmbH (BiomeDx) is world leader in microbiome diagnostic products for oncology. The Austrian based MedTech company is committed to advance precision medicine by pioneering microbiome-based technologies that transform cancer care. The company is strategically positioned at the intersection of state-of-the-art DNA sequencing and advanced machine learning algorithms to develop first in class technologies for routine clinical practice. It is the world first microbiome company certified according to ISO 13485:2016 and ISO 9001:2015.


Follow us on LinkedIn